9 research outputs found
A comprehensive overview of radioguided surgery using gamma detection probe technology
The concept of radioguided surgery, which was first developed some 60 years ago, involves the use of a radiation detection probe system for the intraoperative detection of radionuclides. The use of gamma detection probe technology in radioguided surgery has tremendously expanded and has evolved into what is now considered an established discipline within the practice of surgery, revolutionizing the surgical management of many malignancies, including breast cancer, melanoma, and colorectal cancer, as well as the surgical management of parathyroid disease. The impact of radioguided surgery on the surgical management of cancer patients includes providing vital and real-time information to the surgeon regarding the location and extent of disease, as well as regarding the assessment of surgical resection margins. Additionally, it has allowed the surgeon to minimize the surgical invasiveness of many diagnostic and therapeutic procedures, while still maintaining maximum benefit to the cancer patient. In the current review, we have attempted to comprehensively evaluate the history, technical aspects, and clinical applications of radioguided surgery using gamma detection probe technology
Feeding and reproductive patterns of Astyanax intermedius in a headwater stream of Atlantic Rainforest
Cryptosporidium infection in Brazil: implications for veterinary medicine and public health
Biologia reprodutiva e reprodução induzida de duas espécies de Characidae (Osteichthyes, Characiformes) da bacia do São Francisco, Minas Gerais, Brasil
Racial differences in outcomes for patients with metastatic breast cancer by disease subtype
ECPPA: Randomised trial of low dose aspirin for the prevention of maternal and fetal complications in high risk pregnant women
Objective To determine the effectiveness of low dose aspirin in women at high risk of adverse outcomes associated with pre-eclampsia.Design A collaborative randomised trial comparing the effects of low dose aspirin (60 mg) with placebo on pre-eclampsia and other materno-fetal complications associated with hypertension.Setting Twelve teaching maternity hospitals and 182 obstetricians' offices in Brazil.Subjects One thousand and nine women considered to be at high risk for the development of preeclampsia, or its complications, entered the study between 12 and 32 weeks of gestation. They were randomly allocated to receive aspirin (498 women) or placebo (511 women) until delivery, and follow up was obtained for 96%.Results There were no significant differences between the treatment groups in the incidence of proteinuric pre-eclampsia (6.7% aspirin-allocated compared with 6.0% placebo-allocated women), of preterm delivery (22.3% compared with 26.1%), of intrauterine growth retardation (8.5% compared with 10.1%), or of stillbirth and neonatal death (7.3% compared with 6.0%), nor were there significant differences in the incidence of proteinuric pre-eclampsia in any subgroup of women studied, including those who had systolic blood pressures of 120 mmHg or above at entry (8.5% compared with 7.3%) or those who were chronically hypertensive (10.0% compared with 7.1%). Aspirin was not associated with a significant excess of maternal or fetal bleeding.Conclusion The results of this study do not support the routine prophylactic administration of low dose aspirin in pregnancy to any category of high risk women (even those who have chronic hypertension or who are considered to be especially liable to early onset pre-eclampsia).ESCOLA PAULISTA MED,DEPT MED,MED CLIN D,RUA BOTUCATU 740,BR-04023900 SAO PAULO,BRAZILESCOLA PAULISTA MED,DEPT MED,MED CLIN D,RUA BOTUCATU 740,BR-04023900 SAO PAULO,BRAZILWeb of Scienc
Molecular testing in breast cancer
Molecular testing in breast cancer has been used for many years to guide treatment selection and provide prognostic information, as has been exemplified by the immunohistochemical (IHC) assessment of molecular markers such as ER, PgR, and/or HER2. Additional information can be derived by the assessment of proliferation status achieved through IHC evaluation of Ki67. During the last years, newly emerged technologies have expanded the palette of molecular tests becoming available in breast cancer, namely, gene expression profiling leading to the generation of prognostic gene signatures and gene signatures of specific pathway activation status, circulating tumor cells detection and enumeration methods, and sequencing techniques currently used for the assessment of BRCA1/2 mutational status, with next-generation sequencing methods setting the promise to elucidate the molecular landscape of this common disease. In the present chapter, we provide a comprehensive overview of all molecular tests currently used in breast cancer, giving additional information about newly emerging molecular tests that promise to improve the clinical management of our patients.SCOPUS: ch.binfo:eu-repo/semantics/publishe